The Prostate

publication venue for

TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment. 2023
The diagnostic accuracy of ⁶⁸ Ga-PSMA-PET/CT in primary staging of patients with high-risk nonmetastatic prostate cancer treated with radical prostatectomy: A single-center cohort analysis. 2023
Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate-specific antigen concentrations.. 83. 2023
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy. 2023
Prostate cancer genetic alterations in Hispanic men. 2023
Single-cell analysis of localized prostate cancer patients links high Gleason score with an immunosuppressive profile.. 83. 2023
The association of type and number of high-risk criteria with cancer specific mortality in prostate cancer patients treated with radiotherapy.. 83. 2023
Feasibility and preliminary clinical tolerability of low-field MRI-guided prostate biopsy. 2023
Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.. 83. 2023
Importance of magnetic resonance imaging and prostate-specific membrane antigen PET-CT in patients treated with salvage radical prostatectomy for radiorecurrent prostate cancer.. 83. 2022
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer. 2022
Effect of positive surgical margins at radical prostatectomy on cancer-specific mortality in high/very high-risk prostate cancer patients with Gleason Grade Group 4-5.. 83. 2022
Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.. 82. 2022
Definitive treatment choice among Black immigrants with prostate cancer: Analysis of patient surveys distributed at a single safety-net institution.. 82. 2022
Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level.. 82. 2022
Contemporary seminal vesicle invasion rates in NCCN high-risk prostate cancer patients.. 82. 2022
Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates.. 82. 2022
Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer.. 82. 2022
Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups. 2022
Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients. 2022
Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples. 2022
Pilot study of the diagnostic utility of ⁸⁹ Zr-df-IAB2M and ⁶⁸ Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer. 2022
Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients.. 82. 2021
Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients.. 81. 2021
Increased risk of postoperative in-hospital complications after radical prostatectomy in patients with prior organ transplant.. 81. 2021
Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients.. 81. 2021
Presence of biopsy Gleason pattern 5 + 3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns.. 81. 2021
The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer.. 81. 2021
Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy.. 81. 2021
Tissue clearing techniques for three-dimensional optical imaging of intact human prostate and correlations with multi-parametric MRI.. 81. 2021
The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients.. 81. 2021
Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.. 81. 2021
Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer.. 81. 2020
Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.. 80. 2020
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.. 80. 2019
Response assessment using [⁶⁸ Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer.. 80. 2019
Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages.. 78. 2018
Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.. 78. 2018
Influence of the neural microenvironment on prostate cancer.. 78. 2017
Accuracy of Grading Gleason Score 7 Prostatic Adenocarcinoma on Needle Biopsy: Influence of Percent Pattern 4 and Other Histological Factors.. 77. 2017
Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment.. 77. 2017
Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG.. 77. 2017
North American Population-Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer.. 77. 2017
Population-Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients.. 77. 2016
Neuronal Trans-Differentiation in Prostate Cancer Cells.. 76. 2016
Predictors of biochemical recurrence in pT3b prostate cancer after radical prostatectomy without adjuvant radiotherapy.. 76. 2015
Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC.. 75. 2015
Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [(11) C]acetate PET as a prognostic marker.. 75. 2015
Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor.. 75. 2015
Delay from biopsy to radical prostatectomy influences the rate of adverse pathologic outcomes.. 75. 2015
The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer.. 75. 2015
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.. 75. 2015
Utility of FDG-PET in clinical neuroendocrine prostate cancer.. 74. 2014
Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.. 74. 2013
Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor.. 73. 2013
Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells.. 73. 2013
Negative regulation of NEP expression by hypoxia.. 73. 2012
Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival.. 73. 2012
External validation of the updated Briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection.. 73. 2012
Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality.. 72. 2011
A critical assessment of the value of lymph node dissection at radical prostatectomy: A population-based study.. 71. 2011
Gene expression pathways of high grade localized prostate cancer.. 71. 2011
Down-regulation of microRNA 106b is involved in p21-mediated cell cycle arrest in response to radiation in prostate cancer cells.. 71. 2010
Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity.. 70. 2010
Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.. 70. 2010
Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.. 69. 2009
Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.. 69. 2009
Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence.. 69. 2009
Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells.. 69. 2009
Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells.. 68. 2008
17alpha-estradiol inhibits LAPC-4 prostatic tumor cell proliferation in cell cultures and tumor growth in xenograft animals.. 67. 2007
Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence.. 67. 2007
Regulation of prostate 5alpha-reductase-2 gene expression and prostate weight by dietary fat and caloric intake in the rat.. 66. 2006
Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells.. 66. 2006
Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer.. 65. 2005
Retinoic acid slows progression and promotes apoptosis of spontaneous prostate cancer.. 61. 2004
Differential expression of cell cycle regulatory molecules and evidence for a "cyclin switch" during progression of prostate cancer.. 58. 2004
Apolipoprotein-D: a novel cellular marker for HGPIN and prostate cancer.. 58. 2004
Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate.. 58. 2004
Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.. 58. 2004
Familial aggregation of prostate cancer in African-Americans and white Americans.. 56. 2003
Intermediate basal cells of the prostate: in vitro and in vivo characterization.. 55. 2003
Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model.. 55. 2003
MicroPET imaging of prostate cancer in LNCAP-SR39TK-GFP mouse xenografts.. 55. 2003
Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line.. 55. 2003
The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.. 54. 2003
Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression.. 54. 2003
Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.. 53. 2002
Clinical stage T1c prostate cancer: pathologic outcomes following radical prostatectomy in black and white men.. 50. 2002
Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study.. 47. 2001
Characteristics of normal prostate vascular anatomy as displayed by power Doppler.. 46. 2001
Leptin and prostate cancer.. 46. 2001
Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue.. 33. 1997
MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma.. 33. 1997
Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy.. 29. 1996
Effect of 5-alpha-reductase inhibition and dexamethasone administration on the growth characteristics and intratumor androgen levels of the human prostate cancer cell line PC-3.. 24. 1994
TRPM-2 gene expression in normal rat ventral prostate following castration and exposure to diethylstilbestrol, flutamide, MK-906 (finasteride), and coumarin.. 24. 1994
Comparison of the pathologic features and DNA ploidy value of prostate cancers detectable by sonography and by palpation.. 23. 1993
Characterization of steroid receptors in human prostate using mibolerone.. 8. 1986
Antigrowth effect of polyamine biosynthesis inhibitors on the Dunning R 3327-G prostatic tumor.. 5. 1984
Physicochemical characterization of the androgen receptor from hyperplastic human prostate.. 5. 1984
A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response.. 4. 1983
The patient, disease status, and treatment options for prostate cancer: stages B1 and B2.. 4. 1983
Abnormal levels of plasma hormones in men with prostate cancer: evidence toward a "two-disease" theory.. 3. 1982
Effect of estrogen on the mixed lymphocyte reaction in normal individuals and prostatic cancer patients.. 3. 1982
Effects of estrogen administration on serum testosterone in Copenhagen rats.. 3. 1982
Significance of prostatic biopsies after radiation therapy for carcinoma of the prostate.. 3. 1982
Workgroup 3: transgenic and reconstitution models of prostate cancer. 1998
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. 2020
Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting. 2018
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group. 2018
Meeting Report From the Prostate Cancer Foundation Scientific Working Group on Radium-223. 2016
Response to RL-225Ac in prostate cancer: effect of prior treatment with RL-177Lu: a systematic review of the literature. 2023

VIVO Weill Cornell Medical College

The Prostate Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)